TABLE II.
Clinicopathologic characteristics
| Characteristic | Participant groupa | p Valueb | |
|---|---|---|---|
|
| |||
| Mastectomy | BCT | ||
| AJCC stage [n (%)] | <0.01 | ||
| I | 69 (46.0) | 85 (67.5) | |
| II | 81 (54.0) | 41 (32.5) | |
|
| |||
| T Stage [n (%)] | <0.01 | ||
| T1mic | 6 (4.0) | 2 (1.6) | |
| T1A | 6 (4.0) | 3 (2.4) | |
| T1B | 24 (16.0) | 35 (27.8) | |
| T1C | 46 (30.7) | 55 (43.7) | |
| T2 | 65 (43.3) | 30 (23.8) | |
| T3 | 3 (2.0) | 0 (0) | |
|
| |||
| Mean tumour size (cm) | 2.0 | 1.6 | <0.01c |
|
| |||
| N Stage [n (%)] | 0.036 | ||
| N0 | 105 (70.0) | 102 (80.1) | |
| N1 | 45 (45.0) | 24 (19.0) | |
|
| |||
| ER assay [n (%)] | 0.46 | ||
| Positive | 134 (89.3) | 114 (90.5) | |
| Negative | 16 (10.7) | 10 (7.9) | |
|
| |||
| PgR assay [n (%)] | 0.27 | ||
| Positive | 122 (81.3) | 107 (84.9) | |
| Negative | 28 (18.7) | 17 (13.5) | |
|
| |||
| HER2 assay [n (%)] | 0.32 | ||
| Positive | 13 (25.0) | 5 (12.8) | |
| Negative | 37 (71.2) | 33 (84.6) | |
| Borderline | 2 (3.8) | 1 (2.6) | |
|
| |||
| Combination of receptor assaysd [n (%)] | 0.07 | ||
| Not favourable | 30 (20.8) | 15 (12.4) | |
| Favourable | 114 (79.2) | 106 (87.6) | |
|
| |||
| Tumour grade [n (%)] | 0.07 | ||
| 1 | 31 (22.0) | 34 (27.8) | |
| 2 | 62 (44.0) | 62 (50.8) | |
| 3 | 48 (34.0) | 26 (21.3) | |
|
| |||
| Tumour description [n (%)] | 0.42 | ||
| Infiltrating ductal | 105 (70.0) | 90 (71.4) | |
| Infiltrating lobular | 20 (13.3) | 11 (8.7) | |
| Ductal and lobular | 6 (4.0) | 3 (2.4) | |
| Mucinous adenocarcinoma | 6 (4.0) | 4 (3.2) | |
| Other | 13 (8.7) | 18 (14.3) | |
|
| |||
| Tumour multiplicity counter [n (%)] | 0.34 | ||
| 01 | 110 (79.7) | 110 (87.3) | |
| 02 | 16 (11.6) | 9 (7.1) | |
| 03 | 6 (4.4) | 3 (2.4) | |
| ≥04 | 6 (4.4) | 3 (2.4) | |
|
| |||
| Tumour side [n (%)] | 0.24 | ||
| Left | 81 (54.0) | 59 (46.8) | |
| Right | 69 (46.0) | 67 (53.2) | |
|
| |||
| Tumour location [n (%)] | 0.02 | ||
| Breast othere | 112 (74.7) | 77 (61.1) | |
| Upper outer | 38 (25.3) | 48 (38.9) | |
|
| |||
| Preoperative MRI [n (%)] | 0.05 | ||
| Yes | 90 (60.0) | 61 (48.4) | |
| No | 60 (40.0) | 65 (51.6) | |
a
Denominators vary depending on response rate.
b
By Pearson chi-square test unless otherwise specified. Boldface type denotes significance.
c
By 2-tailed t-test.
d
“Not favourable” combinations: ER−, PgR−, HER2−; ER−, PgR−, HER2+; ER−, PgR+, HER2+; ER+, PgR−, HER2+; and ER+, PgR+, HER2+. “Favourable” combinations: ER+, PgR+, HER2−; ER−, PgR+, HER2−; and ER+, PgR+, HER2−.
e
Breast not otherwise specified, central, lower inner, lower outer, overlap, and upper inner.
BCT = breast-conservation therapy; AJCC = American Joint Committee on Cancer; ER = estrogen receptor; PgR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; MRI = magnetic resonance imaging.